About Stiefel
Stiefel is a company based in Durham (United States) founded in 1847 was acquired by GSK in April 2009. Stiefel has completed 2 acquisitions, including Barrier Therapeutics and Connetics Corporation. Stiefel operates in a competitive market with competitors including Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others.
- Headquarter Durham, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Investments & Acquisitions
Barrier Therapeutics
& 1 more
-
Acquired by
GSK
(Apr 19, 2009)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Stiefel
Detailed funding history for Stiefel
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Stiefel
Stiefel has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include GSK.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
Locked | Locked | Locked |
Investor details for Stiefel
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Stiefel
Stiefel has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Barrier Therapeutics and Connetics Corporation.
Investment portfolio details for Stiefel
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Topical drugs for dermatology disorders were developed.
|
Locked | Locked | 2002 | Locked | |
|
Biopharmaceutical medicines are developed and distributed globally by the company.
|
Locked | Locked | 1993 | Locked |
Complete acquisition details for Stiefel
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Stiefel
Detailed financials for Stiefel
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Stiefel Comparisons
Peer comparison for Stiefel
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Stiefel
Stiefel operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| Locked | Locked | Locked |
Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| Locked | Locked | Locked |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| Locked | Locked | Locked |
Therapeutics for multiple diseases including dermatology and neurology are developed.
|
|
| Locked | Locked | Locked |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
Detailed competitors of Stiefel
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Stiefel
Complete news archive for Stiefel
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stiefel
Stiefel was founded in 1847.
Stiefel is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Stiefel, a subsidiary of GSK, was founded in 1847 and is headquartered in Durham, United States. Operations focus on the dermatology sector, where prescription products for various skin conditions are manufactured and marketed worldwide. A portfolio of seven such products is maintained, supporting advancements in skin science. As the largest independent dermatology company, global reach is emphasized in its activities.
Stiefel's top competitors include Revance Therapeutics, Dermavant and Bausch Health.
Stiefel has made 2 acquisitions, including Barrier Therapeutics, and Connetics Corporation.
Stiefel has 1 investor. Key investors include GSK.